Blueprint Medicines (BPMC) Misses Q1 EPS by 16c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.29), $0.16 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $954 thousand versus the consensus estimate of $2.77 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Morgan Stanley upgrades CDW on stronger AI-driven server demand